Editas Medicine, Inc. - Kapitalisasi pasar EDIT

The global genome editing sector is currently transitioning to a mass-market sales stage, where transplantation centers are driving primary demand. The infrastructure of Editas Medicine, Inc. (EDIT) is based on laboratories in Massachusetts and partnerships with US manufacturing plants. The quotes shown below, fixed at the level of 0.38, illustrate the dynamics of a business that is developing CRISPR therapy, monetizing patents, and seeking treatments for anemia.

EDIT (editasmedicine.com) riwayat Nilai pasar saka 23.10.2026 nganti 23.10.2026

Editas Corp - rincian analitis lan metrik utama (EDIT)

Indikator keuangan lan pasar perusahaan Editas Medicine, Inc. (EDIT):

Rega saham Editas Medicine|EDIT - Prakiraan gabungan firma investasi|Kapitalisasi pasar Editas Corp

Analisis fundamental perusahaan:Editas Medicine EDIT

Produk asli Editas Corp

The analyst assesses the credit quality of Editas Medicine, Inc. (EDIT) through the lens of liquidity and market confidence. The specifics of CRISPR therapy, characterized by patent wars and clinical risks, render the capitalization extremely volatile. The total market value of the business is calculated as the product of the current share price and the total number of outstanding shares. This indicator measures market capital density, reflecting investor expectations regarding the success of high-cost treatments. An increase in this metric absent fundamental achievements signals speculative risk.

Analisis pesaing

Kapitalisasi pasar TEM (Tempus)|QGEN: Kapitalisasi pasar|Ionis Pharma - Kapitalisasi pasar|Kapitalisasi pasar Repligen Inc. RGEN|RNA (Avidity Biosciences) - Biji pasar|CRSP: Nilai pasar|WGS (GeneDx) - Kapitalisasi pasar|Kapitalisasi pasar RARE (Ultragenyx Pharmaceutical Inc.)|Nilai pasar Beam Therapeutics Corp (BEAM)|Sarepta Corp - Kapitalisasi pasar|Kapitalisasi pasar TWST (Twist Bioscience)|Kapitalisasi pasar 10xgenomics.com TXG|Intellia Therapeutics, Inc. - Kapitalisasi pasar|Nilai pasar Stoke Therapeutics Inc|BLFS: Kapitalisasi pasar|Kapitalisasi pasar WVE|MAZE (Maze Therapeutics Inc) - Kapitalisasi pasar|sionnatx.com (SION) - Kapitalisasi pasar|Biji pasar PRME (Prime Medicine)|Nilai pasar TSHA|Kapitalisasi pasar QURE (uniQure Corp)|Kapitalisasi pasar MeiraGTx Corp MGTX|RGNX - Nilai pasar|Kapitalisasi pasar solidbio.com SLDB|OCGN (Ocugen) - Biji pasar|Pacific Biosciences of California, Inc. - Nilai pasar|Nilai pasar Benitec|Biji pasar Design Corp (DSGN)|Kapitalisasi pasar RCKT|FDMT - Nilai pasar|Kapitalisasi pasar LXEO (Lexeo Therapeutics, Inc.)|KRRO: Kapitalisasi pasar|Silence Therapeutics Inc. - Kapitalisasi pasar|Kapitalisasi pasar ProQR Therapeutics N.V. PRQR|CDXS: Kapitalisasi pasar|Biji pasar sangamo.com|NAUT (Nautilus Biotechnology, Inc.) - Kapitalisasi pasar|Metagenomi Inc. (MGX) - Kapitalisasi pasar|Nilai pasar Precision BioSciences (DTIL)|generationbio.com - Kapitalisasi pasar|Kapitalisasi pasar BOLD (Boundless Bio, Inc.)|Exicure Inc. (XCUR) - Nilai pasar|IMNN: Biji pasar|Nilai pasar PHIO (Phio Pharmaceuticals)|MBIO: Kapitalisasi pasar|RNAZ - Kapitalisasi pasar|Nilai pasar Bionano Genomics Inc.|Kapitalisasi pasar APDN (adnas.com)|Kapitalisasi pasar BLUE|Biji pasar immunoprecise.com IPA|Omega - Biji pasar|Kapitalisasi pasar Singular Genomics Corp (OMIC)|Regulus Therapeutics - Kapitalisasi pasar|Nilai pasar syros.com|TBIO: Kapitalisasi pasar|Kapitalisasi pasar TCON|UBX (Unity Bio) - Kapitalisasi pasar